UK-based CRO Charnwood Molecular reveals plans for ‘significant’ expansion in 2021
29th April 2021
Charnwood Molecular recently announced a partnership with private equity fund Synoya to further its expansion plans.
This deal, according to the CRO, provided additional capital to support the company’s future development and growth, including hiring additional senior leadership team members.
The expansion plans include Charnwood Molecular becoming the sole occupier of a ‘state-of-the-art’ laboratory facility at Charnwood Campus, based in Loughborough.
This campus was recently designated a ‘Life Sciences Opportunity Zone’, Charnwood Molecular said in a statement, allowing for greater collaboration and accelerated business growth within the med-tech and biopharma industries.
Charnwood Molecular Unveils Significant Expansion Plans
Search jobs Charnwood Molecular Unveils Significant Expansion Plans
Charnwood Molecular, a leading UK-based pre-clinical discovery CRO servicing the global pharmaceutical and biotechnology market, has unveiled plans for significant expansion in 2021.
Charnwood Molecular continues to build upon its foundation in medicinal chemistry, scale-up chemistry and custom synthesis provision, evolving its business strategy to deliver increasingly high-tech and high-value research capabilities. In order to enable and enhance its ambitious expansion plans, Charnwood Molecular recently partnered with Synova, a leading and award-winning European private equity fund, who have made a significant investment into the business. The deal has provided the company with additional capital to support its future development and growth, including the introduction of additional senior leadership team members into the business.